Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | BMC Medicine

Figure 4

From: Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis

Figure 4

Forest plot of the association of Pv MSP-1 19 IgG responses with Plasmodium vivax outcomes. Estimates represent the estimate of P. vivax infection in IgG responders compared with non-responders unless stated otherwise. For cross-sectional and case-control studies, the estimate is an odds ratio; for cohort studies, it is a risk ratio. 1Meta-analysis of IgG responses to PvMSP-119 and odds of P. vivax infection (estimates from cross-sectional studies) showed a high degree of heterogeneity (I 2 = 73.8%, P = 0.004), so results were not pooled. aData supplied by the original authors, and estimate calculated by the current authors; bestimate calculated by the current authors from data in the paper; cpublished estimate. All estimates are unadjusted, with the exception of estimates from Cole-Tobian et al. [34], which were adjusted for age, and Noguiera et al. [27], which were adjusted for geographical sector. When I 2 was ≤30%, meta-analysis based on a fixed-effects model was conducted. AU, antigen units; LM, light microscopy; PCR, polymerase chain reaction; PNG, Papua New Guinea; RTQ-PCR, real-time quantitative PCR; W, weight.

Back to article page